三生制药(01530)盘中涨超11%,截至发稿,股价上涨10.20%,现报13.18港元,成交额6.08亿港元。
三生制药此前发布止年度业绩,该集团期内取得收入91.08亿元人民币,同比增加16.5%;母公司拥有人应占纯利20.90亿元,同比增加34.9%;每股基本盈利0.86元;拟派发末期股息每股25港仙。公告称,收入增加主要由于特比澳、蔓迪及赛普汀的销售额强势增长。特比澳2024年销售收入约50.62亿元,同比增长20.4%。
中金表示,三生制药财报好于该行预期,主要因核心品种稳健增长及联营公司收益增长。维持“跑赢行业”评级,由于近期港股流动性回暖和板块估值中枢上升,上调目标价68.8%至13.5港元,另认为公司管线布局丰富,创新产品进入收获期。
责任编辑:卢昱君
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.